Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL. 70, 2012, Pages

  Pipitone, Nicolò ^a   Olivieri, Ignazio ^b   Salvarani, C ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Rheumatology Department of Lucania   (Italy)

Author keywords

Biologic agents; Large vessel vasculitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; BENZATHINE PENICILLIN; BIOLOGICAL PRODUCT; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANEURYSM; AORTA ARCH SYNDROME; ARTHRITIS; BEHCET DISEASE; CLINICAL PRACTICE; COGAN SYNDROME; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; FLU LIKE SYNDROME; GE BEHCET SYNDROME; GENITAL ULCER; GIANT CELL ARTERITIS; GONAD DYSFUNCTION; HUMAN; INFUSION RELATED REACTION; IRIDOCYCLITIS; IRIS RUBEOSIS; IRITIS; LARGE VESSEL VASCULITIS; LEUKOPENIA; MEDICAL SOCIETY; MOUTH ULCER; NEPHROTOXICITY; NEURO BEHCET SYNDROME; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAPULOPUSTULAR LESION; PRACTICE GUIDELINE; PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM; PRIORITY JOURNAL; PULMONARY ARTERY ANEURYSM; PUSTULE; RETINA MACULA CYSTOID EDEMA; RETINA NEOVASCULARIZATION; RETINA VASCULITIS; REVIEW; SCLERITIS; SCLEROMALACIA; SINGLE DRUG DOSE; SKIN DEFECT; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; UVEITIS; VASCULITIS; VITRITIS;

BEHCET SYNDROME; BIOLOGICAL AGENTS; COGAN SYNDROME; EVIDENCE-BASED MEDICINE; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OFF-LABEL USE; PATIENT SELECTION; RHEUMATOLOGY; TAKAYASU ARTERITIS; TREATMENT OUTCOME; VASCULITIS; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84863759339     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. XU LY, ESPARZA EM, ANADKAT MJ, CRONE KG, BRASINGTON RD: Cutaneous manifestations of vasculitis. Semin Arthritis Rheum 2009; 38: 348-60.
2. OXFORD CENTRE FOR EVIDENCE-BASED MEDICINE LEVELS OF EVIDENCE: Internet page 2010
3. SFIKAKIS PP, MARKOMICHELAKIS N, ALPSOY E et al.: Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-41.
4. SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. N Engl J Med 1999; 341: 1284-91.
5. PIPITONE N, OLIVIERI I, CANTINI F, TRIOLO G, SALVARANI C: New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006; 18: 3-9.
6. MELIKOGLU M, FRESKO I, MAT C et al.: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
7. ALPSOY E, DURUSOY C, YILMAZ E et al.: Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138: 467-71.
8. DEMIROGLU H, OZCEBE OI, BARISTA I, DUNDAR S, ELDEM B: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial. Lancet 2000; 355. 605-9.
9. CRITERIA FOR DIAGNOSIS OF BEHÇET'S DISEASE: International Study Group for Behçet's Disease: Lancet 1990; 335: 1078-80
10. HORTON R: Retraction: interferon alfa-2b...in Behçet's disease. Lancet 2000; 356: 1292.
11. DEMIROGLU H: Final verdict of the Turkish Supreme Courts. Br J Ophthalmol 2008; 92: 423.
12. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
13. OLIVIERI I, LECCESE P, D'ANGELO S et al.: Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S54-S57.
14. ALPSOY E, YILMAZ E, BASARAN E: Interferon therapy for Behçet's disease. J Am Acad Dermatol 1994; 31: 617-9.
15. HAMURYUDAN V, MORAL F, YURDAKUL S et al.: Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 1994; 21: 1098-100.
16. DEUTER CM, ZIERHUT M, MOHLE A, VONTHEIN R, STOBIGER N, KOTTER I: Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 2010; 62: 2796-805.
17. KOTTER I, GUNAYDIN I, ZIERHUT M, STUBIGER N: The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 2004; 33: 320-35.
18. SHAPIRO LS, FARRELL J, BORHANI HA: Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin Neurol Neurosurg 2012; 114: 297-8..
19. HIROHATA S, ISSHI K, OGUCHI H et al.: Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin Immunol Immunopathol 1997; 82: 12-7.
20. HAMZAOUI K, HAMZAOUI A, GUEMIRA F, BESSIOUD M, HAMZA M, AYED K: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31. 205-10.
21. BARDAK Y, ARIDOGAN BC: The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm 2004; 12: 53-8.
22. YAMADA Y, SUGITA S, TANAKA H, KAMOI K, KAWAGUCHI T, MOCHIZUKI M: Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010; 94: 284-8.
23. HATEMI G, SILMAN A, BANG D et al.: EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
24. KAKLAMANI VG, KAKLAMANIS PG: Treatment of Behçet's disease-an update. Semin Arthritis Rheum 2001; 30. 299-312.
25. LIN P, LIANG G: Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006; 12: 282-6.
26. SALVARANI C, CANTINI F, HUNDER GG: Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45.
27. MAHR AD, JOVER JA, SPIERA RF et al.: Adjunctive methotrexate to treat giant cell arteritis: an individual patient data metaanalysis. Arthritis Rheum 2007; 56. 2789-97.
28. DE SILVA M, HAZLEMAN BL: Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8.
29. PROVEN A, GABRIEL SE, ORCES C, O'FALLON WM, HUNDER GG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
30. FIELD M, COOK A, GALLAGHER G: Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997; 17: 113-8.
31. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294-301.
32. NORDBORG E, NORDBORG C: The inflammatory reaction in giant cell arteritis: an immunohistochemical investigation. Clin Exp Rheumatol 1998; 16. 165-8.
33. UTHMAN I, KANJ N, ATWEH S: Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006; 25: 109-10.
34. ANDONOPOULOS AP, MEIMARIS N, DAOUSSIS D, BOUNAS A, GIANNOPOULOS G: Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003; 62. 1116.
35. LEYDET-QUILICI H, LUC M, ARMINGEAT T, PHAM T, LAFFORGUE P: Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 2007; 74: 303-4.
36. SETON M: Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 2004; 31: 1467.
37. HOFFMAN GS, CID MC, RENDT-ZAGAR KE et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
38. MARTINEZ-TABOADA VM, RODRIGUEZVALVERDE V, CARRENO L et al.: A doubleblind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-30.
39. AIRO P, ANTONIOLI CM, VIANELLI M, TONIATI P: Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002; 41: 347-9.
40. TORRENTE SV, GUERRI RC, PEREZ-GARCIA C, BENITO P, CARBONELL J: Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha. Intern Med J 2007; 37: 280-1.
41. AHMED MM, MUBASHIR E, HAYAT S, FOWLER M, BERNEY SM: Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007; 26: 1353-5.
42. CANTINI F, NICCOLI L, SALVARANI C, PADULA A, OLIVIERI I: Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-5.
43. TAN AL, HOLDSWORTH J, PEASE C, EMERY P, MCGONAGLE D: Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003; 62: 373-4.
44. MAYRBAEURL B, HINTERREITER M, BURGSTALLER S, WINDPESSL M, THALER J: The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol 2007; 26. 1597-8.
45. BHATIA A, ELL PJ, EDWARDS JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005; 64. 1099-100.
46. NISHIMOTO N, KISHIMOTO T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2. 619-26.
47. ROCHE NE, FULBRIGHT JW, WAGNER AD, HUNDER GG, GORONZY JJ, WEYAND CM: Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36. 1286-94.
48. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
49. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
50. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-23.
51. VANOLI M, DAINA E, SALVARANI C et al.: Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum 2005; 53: 100-7.
52. HENES JC, MUELLER M, PFANNENBERG C, KANZ L, KOETTER I: Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29 (Suppl. 64): S43-S48.
53. MOK CC, LAU CS, WONG RW: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-7.
54. DOOLEY MA, NAIR R: Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol 2008; 4. 250-7.
55. MAKSIMOWICZ-MCKINNON K, CLARK TM, HOFFMAN GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 56. 1000-9.
56. HOFFMAN GS, MERKEL PA, BRASINGTON RD, LENSCHOW DJ, LIANG P: Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.
57. MOLLOY ES, LANGFORD CA, CLARK TM, GOTA CE, HOFFMAN GS: Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67: 1567-9.
58. DELLA RA, TAVONI A, MERLINI G et al.: Two Takayasu arteritis patients successfully treated with infliximab: a potential diseasemodifying agent? Rheumatology (Oxford) 2005; 44: 1074-5.
59. MAFFEI S, DI RENZO M, SANTORO S, PUCCETTI L, PASQUI AL: Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 2009; 13: 63-5.
60. TATO F, RIEGER J, HOFFMANN U: Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005; 24. 304-7.
61. KARAGEORGAKI ZT, MAVRAGANI CP, PAPATHANASIOU MA, SKOPOULI FN: Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 2007; 26. 984-7.
62. TANAKA F, KAWAKAMI A, IWANAGA N et al.: Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006; 45: 313-6.
63. HOYER BF, MUMTAZ IM, LODDENKEMPER K et al.: Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71. 75-9.
64. NISHIMOTO N, NAKAHARA H, YOSHIOHOSHINO N, MIMA T: Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
65. SALVARANI C, MAGNANI L, CATANOSO MG et al.: Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012 Feb 27. [Epub ahead of print].
66. DASGUPTA B, BORG FA, HASSAN N et al.: BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010; 49: 1594-7.
67. HOFFMAN GS, LEAVITT RY, KERR GS, ROTTEM M, SNELLER MC, FAUCI AS: Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.
68. VALSAKUMAR AK, VALAPPIL UC, JORAPUR V, GARG N, NITYANAND S, SINHA N: Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003; 30. 1793-8.
69. SHINJO SK, PEREIRA RM, TIZZIANI VA, RADU AS, LEVY-NETO M: Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007; 26: 1871-5.
70. GRASLAND A, POUCHOT J, HACHULLA E, BLETRY O, PAPO T, VINCENEUX P: Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology (Oxford) 2004; 43: 1007-15.
71. GHADBAN R, COURET M, ZENONE T: Efficacy of infliximab in Cogan's syndrome. J Rheumatol 2008; 35: 2456-8.
72. TOUMA Z, NAWWAR R, HADI U, HOURANI M, ARAYSSI T: The use of TNF-alpha blockers in Cogan's syndrome. Rheumatol Int 2007; 27: 995-6.
73. FRICKER M, BAUMANN A, WERMELINGER F, VILLIGER PM, HELBLING A: A novel therapeutic option in Cogan diseases? TNFalpha blockers. Rheumatol Int 2007; 27: 493-5.
74. AEBERLI D, OERTLE S, MAURON H, REICHENBACH S, JORDI B, VILLIGER PM: Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132. 414-22.
75. MATTESON EL, CHOI HK, POE DS et al.: Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum 2005; 53. 337-42.
76. SALVARANI C, BROWN RD, JR., CALAMIA KT et al.: Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62: 442-51.
77. SALVARANI C, BROWN RD, JR., CALAMIA KT et al.: Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment. Arthritis Rheum 2008; 59: 291-6.
78. SKVARA H, DUSCHEK N, KARLHOFER F: De novo tuberculosis during infliximab therapy in a patient with Behçet disease. J Dtsch Dermatol Ges 2009; 7: 616-9.
79. TRIOLO G, VADALA M, ACCARDO-PALUMBO A et al.: Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002; 61: 560-1.
80. OHNO S, NAKAMURA S, HORI S et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-8.
81. IWATA S, SAITO K, YAMAOKA K et al.: Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behçet's disease. Rheumatology (Oxford) 2009; 48: 1012-3.
82. HIDALGO-TENORIO C, SABIO-SANCHEZ JM, LINARES PJ, SALMERON LM, ROS-DIE E, JIMENEZ-ALONSO J: Magic syndrome and true aortic aneurysm. Clin Rheumatol 2008; 27: 115-7.
83. NAKAMURA S, OHNO S: Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease. Int Ophthalmol Clin 2005; 45: 179-89.
84. SARWAR H, MCGRATH H, JR., ESPINOZA LR: Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005; 32: 181-3.
85. KATSIARI CG, THEODOSSIADIS PG, KAKLAMANIS PG, MARKOMICHELAKIS NN, SFIKAKIS PP: Successful long-term treatment of refractory Adamantiades-Behçet's disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol 2003; 528: 551-5.
86. CONNOLLY M, ARMSTRONG JS, BUCKLEY DA: Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol 2005; 153: 1073-5.
87. ROZENBAUM M, ROSNER I, PORTNOY E: Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002; 61: 283-4.
88. TRAVIS SP, CZAJKOWSKI M, MCGOVERN DP, WATSON RG, BELL AL: Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-8.
89. GOOSSENS PH, VERBURG RJ, BREEDVELD FC: Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60: 637.
90. ROBERTSON LP, HICKLING P: Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40: 473-4.
91. GULLI S, ARRIGO C, BOCCHINO L et al.: Remission of Behçet's disease with antitumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003; 4: 19.
92. OLIVIERI I, LATANZA L, SIRINGO S, PERUZ G, DI IORIO V: Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 2008; 35: 930-2.
93. OLIVIERI I, PADULA A, LECCESE P, D'ANGELO S, GIASI V: Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 2009; 36: 855.
94. HANDA T, TSUNEKAWA H, YONEDA M et al.: Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S58-S63.
95. IWATA S, SAITO K, YAMAOKA K et al.: Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011; 21: 184-91.
96. AIKAWA NE, GONCALVES C, SILVA CA, GONCALVES C, BONFA E, DE CARVALHO JF: Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int 2011; 31: 1097-9.
97. VAN LAAR JA, MISSOTTEN T, VAN DAELE PL, JAMNITSKI A, BAARSMA GS, VAN HAGEN PM: Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007; 66: 565-6
98. LECCESE P, LATANZA L, D'ANGELO S, PADULA A, OLIVIERI I: Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S93.
99. DE CC, DE VB, DUSSAULT C, HACHULLA E, BUCHE S, COLOMBEL JF: Successful treatment with adalimumab in a familial case of gastrointestinal Behçet's disease. J Crohns Colitis 2011; 5: 364-8.
100. CHOU CT: The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 2006; 16: 206-13.
101. ESTRACH C, MPOFU S, MOOTS RJ: Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002; 41: 1213-4.
102. CURIGLIANO V, GIOVINALE M, FONNESU C et al.: Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clin Rheumatol 2008; 27: 933-6.
103. SCHEINBERG MA: Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 2002; 20. 733-4.
104. ATZENI F, SARZI-PUTTINI P, CAPSONI F, MECCHIA M, MARRAZZA MG, CARRABBA M: Successful treatment of resistant Behçet's disease with etanercept. Clin Exp Rheumatol 2005; 23; 729.
105. SOMMER A, ALTMEYER P, KREUTER A: A case of mucocutaneous Behçet's disease responding to etanercept. J Am Acad Dermatol 2005; 52. 717-9.
106. KRAUSE L, ALTENBURG A, PLEYER U, KOHLER AK, ZOUBOULIS CC, FOERSTER MH: Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. J Rheumatol 2008; 35: 896-903.
107. AOKI T, TANAKA T, AKIFUJI Y et al.: Beneficial effects of interferon-alpha in a case with Behçet's disease. Intern Med 2000; 39. 667-9.
108. GEORGIOU S, MONASTIRLI A, PASMATZI E, GARTAGANIS S, GOERZ G, TSAMBAOS D: Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med 1998; 243: 367-72.
109. DURUSOY C, ALPSOY E, YILMAZ E: Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A. J Dermatol 1999; 26. 225-8.
110. GRIMBACHER B, WENGER B, DEIBERT P, NESS T, KOETTER I, PETER HH: Loss of vision and diarrhoea. Lancet 1997; 350. 1818.
111. BOYVAT A, SISMAN-SOLAK C, GURLER A: Long-term effects of interferon alpha 2A treatment in Behçet's disease. Dermatology 2000; 201: 40-3.
112. AZIZLERLI G, SARICA R, KOSE A et al.: Interferon alfa-2a in the treatment of Behçet's disease. Dermatology 1996; 192: 239-41.
113. CHRONI E, MONASTIRLI A, POLYCHRONOPOULOS P et al.: Epileptic seizures as the sole manifestation of neuro-Behçet's disease: complete control under interferonalpha treatment. Seizure 2008; 17: 744-7.
114. HAUGEBERG G, VELKEN M, JOHNSEN V: Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004; 63: 744-5.
115. KASUGAI C, WATANABE D, MIZUTANI K et al.: Infliximab treatment of severe genital ulcers associated with Behçet disease. J Am Acad Dermatol 2010; 62: 162-4.
116. COBELLIS L, PECORI E, RIGATTI F et al.: Therapeutic alternatives in Behçet's syndrome. Clin Exp Obstet Gynecol 2007; 34. 151-3.
117. NICHOLS JC, INCE A, AKDUMAN L, MANN ES: Interferon-alpha 2a treatment of neuro-Behçet disease. J Neuroophthalmol 2001; 21: 109-11.
118. SAKELLARIOU G, BERBERIDIS C, VOUNOTRYPIDIS P: A case of Behçet's disease with scleromalacia perforans. Rheumatology (Oxford) 2005; 44: 258-60.
119. TUGAL-TUTKUN I, MUDUN A, URGANCIOGLU M et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84.
120. JALILI A, KINACIYAN T, BARISANI T et al.: Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab. Iran J Immunol 2009; 6: 55-8.
121. NICCOLI L, NANNINI C, BENUCCI M et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46: 1161-4.
122. LINDSTEDT EW, BAARSMA GS, KUIJPERS RW, VAN HAGEN PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89: 533-6.
123. BENITEZ-DEL-CASTILLO JM, MARTINEZDE-LA-CASA JM, PATO-COUR E et al.: Longterm treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab). Eye (Lond) 2005; 19: 841-5.
124. JOSEPH A, RAJ D, DUA HS, POWELL PT, LANYON PC, POWELL RJ: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-53.
125. ABU EL-ASRAR AM, ABBOUD EB, ALDIBHI H, AL ARFAJ A: Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005; 26: 83-92.
126. SARI I, BIRLIK M, GONEN C et al.: Cytomegalovirus colitis in a patient with Behçet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912-4.
127. TOGNON S, GRAZIANI G, MARCOLONGO R: Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007; 1110: 474-84.
128. LANTHIER N, PARC C, SCAVENNEC R, DHOTE R, BREZIN AP, GUILLEVI L: Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005; 34: 916-8.
129. ACCORINTI M, PIRRAGLIA MP, PAROLI MP, PRIORI R, CONTI F, PIVETTI-PEZZI P: Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007; 51: 191-6.
130. SAYARLIOGLU M, CINAL A, TOPCU N, DEMIROK A: Effect of infliximab on refractory uveitis in Behçet's disease. Ann Pharmacother 2004; 38: 901-2.
131. WECHSLER B, SABLE-FOURTASSOU R, BODAGHI B et al.: Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S14-S16.
132. ARAYSSI T, HAMRA R, HOMEIDAN F et al.: The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis. Clin Exp Rheumatol 2005; 23: 427.
133. ALOKAILY F, ALSALEH S, AL-BALAWI M, AL-RASHIDI S: Efficacy of infliximab on the acute attack of uveitis. Saudi Med J 2010; 31: 82-5.
134. FASANO A, D'AGOSTINO M, CALDAROLA G, FELICIANI C, DE SC: Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies. J Neuroimmunol 2011; 239: 105-7.
135. ITO T, SONODA KH, HIJIOKA K, FUJIMOTO T, ISHIBASHI T: Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration. Jpn J Ophthalmol 2010; 54: 502-4.
136. ADAN A, HERNANDEZ V, ORTIZ S et al.: Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol 2010; 30: 577-81.
137. GIARDINA A, FERRANTE A, CICCIA F, VADALA M, GIARDINA E, TRIOLO G: One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31: 33-7.
138. TAKASE K, OHNO S, IDEGUCHI H, UCHIO E, TAKENO M, ISHIGATSUBO Y: Successful switching to adalimumab in an infliximaballergic patient with severe Behçet diseaserelated uveitis. Rheumatol Int 2011; 31: 243-5.
139. SOBACI G, ERDEM U, DURUKAN AH et al.: Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 2010; 117: 1430-5.
140. MUNOZ-FERNANDEZ S, HIDALGO V, FERNANDEZ-MELON J, SCHLINCKER A, MARTINMOLA E: Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001; 358: 1644.
141. SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN: Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-6.
142. MUSHTAQ B, SAEED T, SITUNAYAKE RD, MURRAY PI: Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007; 21: 824-5.
143. STONE JH, PAPALIODIS GN, COSTELLO DJ: A 29-year-old woman with headache, fever, right leg numbness, and dysphagia. Arthritis Care Res (Hoboken) 2010; 62: 283-90.
144. YAMADA Y, SUGITA S, TANAKA H, KAMOI K, TAKASE H, MOCHIZUKI M: Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol 2011; 95: 205-8.
145. KANE D, BALINT PV, WOOD F, STURROCK RD: Early diagnosis of pyomyositis using clinic-based ultrasonography in a patient receiving infliximab therapy for Behçet's disease. Rheumatology (Oxford) 2003; 42: 1564-5.
146. TAKAMOTO M, KABURAKI T, NUMAGA J, FUJINO Y, KAWASHIMA H: Long-term infliximab treatment for Behçet's disease. Jpn J Ophthalmol 2007; 51: 239-40.
147. SFIKAKIS PP, KAKLAMANIS PH, ELEZOGLOU A et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004; 140: 404-6.
148. AL RAYES H, AL SWAILEM R, AL BALAWI M, AL DOHAYAN N, AL ZAIDI S, TARIQ M: Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int 2008; 29: 53-7.
149. TABBARA KF, AL HEMIDAN AI: Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008; 146: 845-50.
150. KEINO H, OKADA AA, WATANABE T, TAKI W: Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245-50.
151. DONGHI D, MAINETTI C: Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatology 2010; 220: 282-6.
152. GIANSANTI F, BARBERA ML, VIRGILI G, PIERI B, EMMI L, MENCHINI U: Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 2004; 14: 445-8.
153. YUCEL AE, KART-KOSEOGLU H, AKOVA YA, DEMIRHAN B, BOYACIOGLU S: Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology (Oxford) 2004; 43: 394-6.
154. MANSOUR AM: Infliximab treatment of posterior uveitis. Ophthalmology 2004; 111: 197-8.
155. BAWAZEER A, RAFFA LH, NIZAMUDDIN SH: Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010; 18: 226-32.
156. ONAL S, KAZOKOGLU H, KOC A et al.: Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 2011; 129: 288-94.
157. TUGAL-TUTKUN I, GUNEY-TEFEKLI E, URGANCIOGLU M: Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1692-5.
158. WECHSLER B, BODAGHI B, HUONG DL et al.: Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000; 8: 293-301.
159. KOTTER I, ZIERHUT M, ECKSTEIN AK et al.: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423-31.
160. BODAGHI B, GENDRON G, WECHSLER B et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007; 91: 335-9.
161. GUEUDRY J, WECHSLER B, TERRADA C et al.: Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008; 146: 837-44.
162. HAMURYUDAN V, OZYAZGAN Y, FRESKO Y, MAT C, YURDAKUL S, YAZICI H: Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 2002; 4: 928-30.
163. DURAND JM, KAPLANSKI G, TELLE H, SOUBEYRAND J, PAULO F: Beneficial effects of interferon-alpha 2b in Behçet's disease. Arthritis Rheum 1993; 36: 1025-6.
164. KOTTER I, VONTHEIN R, ZIERHUT M et al.: Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33: 311-9.
165. KRAUSE L, HOFFMANN F, ZOUBOULIS CC, FOERSTER MH: Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report. Graefes Arch Clin Exp Ophthalmol 2003; 241: 871-4.
166. MANSOUR AM: Infliximab treatment of posterior uveitis. Ophthalmology 2004; 111: 197-8.
167. FERON EJ, ROTHOVA A, VAN HAGEN PM, BAARSMA GS, SUTTORP-SCHULTEN MS: Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994; 343: 1428.
168. STUEBIGER N, KOETTER I, ZIERHUT M: Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 2000; 84: 1437-8.
169. TUGAL-TUTKUN I, ONAL S, ALTAN-YAYCIOGLU R, KIR N, URGANCIOGLU M: Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol 2006; 50: 256-65.
170. SADREDDINI S, NOSHAD H, MOLAEEFARD M, NOSHAD R: Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 2008; 18: 306-8.
171. MADANAT WY, MADANAT AY: Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab. Clin Exp Rheumatol 2008; 26: S128-S129.
172. LICATA G, PINTO A, TUTTOLOMONDO A et al.: Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003; 62: 280-1.
173. PIPITONE N, OLIVIERI I, PADULA A et al.: Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008; 59: 285-90.
174. FUJIKAWA K, ARATAKE K, KAWAKAMI A et al.: Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007; 66: 136-7.
175. KIKUCHI H, ARAMAKI K, HIROHATA S: Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008; 272: 99-105.
176. RIBI C, SZTAJZEL R, DELAVELLE J, CHIZZOLINI C: Efficacy of TNF-alpha blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005; 76: 1733-5.
177. BELZUNEGUI J, LOPEZ L, PANIAGUA I, INTXAUSTI JJ, MAIZ O: Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S133-S134.
178. BORHANI HA, SAFARI A: Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Clin Neurol Neurosurg 2008; 110: 315-6.
179. ALTY JE, MONAGHAN TM, BAMFORD JM: A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNF-alpha blockade. Clin Neurol Neurosurg 2007; 109: 279-81.
180. BORHANI HA, SAFARI A, NAZARINIA MA, HABIBAGAHI Z, SHENAVANDEH S: Infliximab for patients with neuro-Behçet's disease: case series and literature review. Clin Rheumatol 2011; 30: 1007-12.
181. MATSUI T, ISHIDA T, TONO T, YOSHIDA T, SATO S, HIROHATA S: An attack of acute neuro-Behcet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. Mod Rheumatol 2010; 20: 621-6.
182. MEKINIAN A, LAMBERT M, BEREGI JP et al.: Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF-alpha and stent grafting. Rheumatology (Oxford) 2009; 48: 1169-70.
183. BAKI K, VILLIGER PM, JENNI D, MEYER T, BEER JH: Behçet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 2006; 65: 1531-2.
184. TOLOSA-VILELLA C, CAPELA CA, MONTEAGUDO-JIMENEZ M, MARI-ALFONSO B: Infliximab for life-threatening pulmonary artery aneurysms in Behçet's disease. A case report. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S94-S95.
185. SEYAHI E, HAMURYUDAN V, HATEMI G et al.: Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behçet's syndrome. Rheumatology (Oxford) 2007; 46: 1213-4.
186. LEE SW, LEE SY, KIM KN, JUNG JK, CHUNG WT: Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report. Clin Rheumatol 2010; 29: 91-3.
187. MUSSACK T, LANDAUER N, LADURNER R et al.: Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab. Am J Gastroenterol 2003; 98:703-4.
188. BYEON JS, CHOI EK, HEO NY et al.: Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007; 50: 672-6.
189. HASSARD PV, BINDER SW, NELSON V, VASILIAUSKAS EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001; 120: 995-9.
190. NAGANUMA M, SAKURABA A, HISAMATSU T et al.: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008; 14: 1259-64.
191. LEE JH, KIM TN, CHOI ST et al.: Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007; 22: 24-7.
192. JU JH, KWOK SK, SEO SH, YOON CH, KIM HY, PARK SH: Successful treatment of lifethreatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007; 26: 1383-5.
193. KRAM MT, MAY LD, GOODMAN S, MOLINAS S: Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46: 118-21.